This clinical trial is focused on studying the effects of a medication called evolocumab, also known by its code name AMG145, in patients who have experienced an acute myocardial infarction, commonly known as a heart attack. The study aims to compare the effectiveness of evolocumab, administered as a solution for injection, with standard treatment strategies in achieving specific cholesterol level goals. The main goal is to see if evolocumab can help reduce levels of LDL cholesterol, often referred to as “bad” cholesterol, by at least 50% and reach a target level of less than 1.4 mmol/L (or 55 mg/dL) over a period of 12 months.

Participants in the study will be randomly assigned to receive either evolocumab or the usual care strategies. The study will follow participants for up to 36 months, with regular check-ups to monitor cholesterol levels and other health indicators. These check-ups will occur at various intervals, including 6 weeks, 22 weeks, and 12 months after starting the treatment, and may continue up to 24 months or longer, depending on the availability of data. The study will also look at how quickly participants can reach their target cholesterol levels and any changes in other types of cholesterol and fats in the blood.

The purpose of this study is to determine if evolocumab is more effective than standard treatments in helping patients who have had a heart attack achieve healthier cholesterol levels, which could potentially reduce the risk of future heart-related problems. By participating in this study, researchers hope to gather valuable information that could improve treatment strategies for managing cholesterol levels in patients with heart disease.